


Cadeirydd/Chair: Emma Woollett Prif Weithredwr/Chief Executive: Mark Hackett

gofalu am ein gilydd, cydweithio, gwella bob amser caring for each other, working together, always improving

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 12 th January	2021
Ein Cyf / Our Ref: 20-L-013	





C FOIA.Requests@wales.nhs.uk

Corporate Services Headquarters 1 Talbot Gateway Baglan Port Talbot, SA12 7BR

Dear

I refer to your Freedom of Information Act Request acknowledged by ourselves on 15th December 2020. Your request sought information relating to myelofibrosis and oesophageal cancer.

Please note that the information we have provided covers the period 1^{st} May 2020 to 31^{st} October 2020.

- 1. Does your Health Board treat the following conditions? If not, which other trust do you refer these patients to?
 - Advanced oesophageal cancer Yes
 - Myelofibrosis Yes
- 2. Please provide the total number of patients treated in the last 6 months for:
 - **Myelofibrosis** There are no new diagnosis of myelofibrosis recorded on our system.
 - Myelofibrosis patients over the age 65 as above
 - Oesophageal cancer (any type) 16
 - Oesophageal adenocarcinoma 11
 - Oesophageal squamous cell carcinoma <5*
 - Unresectable Oesophageal squamous cell carcinoma 0 (no cases recorded as unresectable)



Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR

Bwrdd lechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd lechyd Lleol Prifysgol Bae Abertawe Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

- **3.** For the oesophageal squamous cell carcinoma patients only, how many patients were treated in the past 6 months with:
 - Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) - <5*
 - Any other systemic anti-cancer therapy <5*
 - **Palliative care only** To obtain this information would involve a manual trawl and search of patient records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

4. For myelofibrosis patients only, how many patients (of any age) were treated in the past 6 months with;

Please note that our system does not separate out myelofibrosis from other myeloproliferative disorders (MPD) therefore numbers provided are for all MPD patients not just those with myelofibrosis.

- Ruxolitinib 6
- Hydroxyurea 91
- Watch and wait approach To obtain this information would involve a manual trawl and search of patient records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

5. Does your Health Board participate in any clinical trials for oesophageal cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

<u>Add-Aspirin - A phase III, double-blind, placebo controlled, randomised trial</u> <u>assessing the effects of aspirin on disease recurrence and survival after primary</u> <u>therapy in common non-metastatic solid tumours (includes an Oesophageal cancer</u> <u>cohort)</u>

<5* patients taking part.

6. Does your Health Board participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part?

No trials open during the time period specified.

* Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

I hope this information is helpful. If you require anything further please contact us at <u>FOIA.Requests@wales.nhs.uk</u>.

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via <u>FOIA.Requests@wales.nhs.uk</u>.

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely

P. a. werye

Pam Wenger Director of Corporate Governance